New Blood Test Reduces Stress in Cancer Research Mice – Uses Firefly Enzymes

Researchers at the University of Marburg in Germany have developed a new blood test designed to improve the monitoring of tumor growth in laboratory mice, potentially reducing animal stress and refining cancer research. The test, detailed in a recent publication in Nature Protocols, allows for a less invasive assessment of tumor burden compared to traditional imaging techniques.

Animal testing remains a crucial component of early-stage drug research, as mandated by regulations in Germany and Europe, to establish safety before human trials. However, the ethical considerations surrounding animal research are paramount. This new method aligns with the “3R principle” – reduce, replace, and refine – aiming to minimize the number of animals used, replace animal testing with alternatives where possible, and improve procedures to lessen animal suffering.

Blood Test Uses Enzymes That Make Fireflies Glow

While cell cultures offer valuable insights, animal models are still essential for understanding complex aspects of cancer, such as early tumor stages and the interplay between tumors and the immune system, according to researchers. The new blood test offers a way to refine these experiments and reduce animal distress.

The core of the technique involves marking tumor cells with secreted luciferases – enzymes that produce light signals, similar to those found in fireflies. These luciferases are released into the bloodstream by the tumor cells, and the concentration of these enzymes directly correlates with tumor growth. “These luciferases are released into the blood by the tumor cells, with their concentration reflecting the tumor growth – the larger the tumor becomes, the stronger the light signals can be measured in the blood,” the University of Marburg explained in a press statement.

This method is applicable to various cancer types and can be used to monitor both transplanted tumors and those that develop spontaneously within the animal, including those in internal organs like the lungs or pancreas. The test provides a dynamic measure of tumor progression, allowing researchers to track changes over time with greater sensitivity and less intervention.

The development of this blood test builds upon decades of research into bioluminescence and its applications in biomedical science. Scientists have long utilized the light-producing capabilities of organisms like fireflies to study biological processes. A 2013 study published in Cancer Discovery highlighted the use of genetically engineered mouse models and coupled luciferase reporters for in vivo cancer system analysis, demonstrating the potential of bioluminescent imaging for longitudinal cancer studies.

More recently, advances in liquid biopsy technology have focused on detecting circulating tumor DNA (ctDNA) in the bloodstream. A study from MIT published in January 2024 detailed a new method for recovering significantly more ctDNA from blood samples, potentially improving the sensitivity of liquid biopsies for cancer detection and monitoring. While the University of Marburg’s approach utilizes luciferase enzymes rather than ctDNA, both represent significant steps forward in non-invasive cancer monitoring.

research at Stanford Medicine has led to the development of an RNA-based blood test capable of detecting cancers, tracking treatment resistance, and assessing tissue injury. This test analyzes cell-free RNA molecules in the bloodstream, offering another avenue for early cancer detection and personalized medicine. The Stanford test, like the University of Marburg’s method, represents a shift towards less invasive diagnostic and monitoring techniques.

“The method presented here impressively shows that excellent research and high ethical standards are not a contradiction,” stated Gert Bange, Vice President of Research at the University of Marburg. The researchers hope that by publishing their protocol in Nature Protocols, they will enable other scientists to adopt and refine the technique, further contributing to the advancement of cancer research while prioritizing animal welfare.

The development of this new blood test represents a significant step towards more refined and ethical cancer research. By reducing animal stress and providing a sensitive method for monitoring tumor growth, this technique has the potential to accelerate the development of new cancer therapies and improve outcomes for patients.